Generative AI in pharmaceutical R&D: From large language models to AI agents to regulation
Генеративный искусственный интеллект в фармацевтических исследованиях и разработках: от больших языковых моделей к ИИ-агентам и регулированию
2026-01-01
SCID: 54.1/qryactns
Discuss with AI
AI agentsGenerative AIfoundation modelspharmaceutical R&Dstatistical programming
Figures from the paper
Abstract (AI)
• Generative AI (GenAI) algorithms have started to make inroads into pharmaceutical R&D. • The DISRUPT-DS roundtable, a forum that brings together data science leaders from major pharmaceutical companies, has recently conducted an analysis of the impact of GenAI on R&D so far. • Here, the roundtable participants report key findings from this effort. • We discuss areas that are regulatory-relevant, including GenAI-powered document drafting and statistical programming, and we explore emerging topics such as the use of autonomous AI agents and foundation models. Generative AI (GenAI) is reshaping pharmaceutical R&D, offering transformative potential across research and development. Applications of GenAI include scientific insight generation, mining large biological datasets to study diseases, molecule design, clinical document drafting, and many others. The DISRUPT-DS roundtable, a forum that brings together data science leaders from major pharmaceutical companies, has recently conducted an analysis of GenAI in R&D. Here, the roundtable participants report key findings from this effort. Specifically, we discuss areas that are regulatory-relevant, including GenAI-powered document drafting and statistical programming, and we explore emerging topics, such as artificial intelligence (AI) agents and foundation models. The goal of this work is to provide an industry-wide perspective of where GenAI is today and how it might evolve in the future.
Key Findings
1
Autonomous AI agents and foundation models are emerging topics expected to influence the future development of GenAI-enabled pharmaceutical R&D.
2
GenAI offers transformative potential across research and development, but the abstract does not report quantitative performance results or validated regulatory outcomes.
3
Generative AI is already being applied across pharmaceutical R&D, including scientific insight generation, biological data mining, molecule design, and clinical document drafting.
4
Regulatory-relevant applications include GenAI-assisted document drafting and statistical programming, requiring focused consideration in pharmaceutical development.
5
The DISRUPT-DS roundtable provides an industry-wide analysis of GenAI’s current impact and likely future evolution in pharmaceutical R&D.
Research Object
Generative AI applications in pharmaceutical research and development
Research Subject
The current and future impact, applications, regulatory relevance, and evolution of generative AI—including large language models, autonomous AI agents, and foundation models—in pharmaceutical R&D
Publication Details
Publication Date
2026-01-01
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest